Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For Zilurgisertib Showing 99.9% Reduction In New HO Lesion Volume In Fibrodysplasia Ossificans Progressiva Patients At Week 24

Benzinga Newsdesk www.benzinga.com Positive 87.1%

Neg 0% Neu 0% Pos 87.1%

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP
- U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review

Comments

No comments yet. Be the first!